-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is the second most prevalent hematological malignancy worldwide
ABBV-383, a B cell maturation antigen × CD3 T cell-binding bispecific antibody, has shown promising results in an ongoing first-in-human Phase I study in relapsed/refractory multiple myeloma (RRMM) result
The study enrolled patients with RRMM who had received at least three previous lines of therapy (including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies) to receive intravenous infusion of ABBV-383 every 3 weeks
As of January 8, 2022, a total of 124 patients (dose escalation [0.
Among evaluable patients (n=122), the objective response rate (ORR) was 57%, and the very good partial response or better (≥VGPR) rate was 43%
In conclusion, ABBV-383 was well tolerated in patients with RRMM, with an objective response rate of 68% at doses ≥ 40 mg
Original source:
D'Souza Anita, Shah Nina, Rodriguez Cesar et al.